178 related articles for article (PubMed ID: 31056940)
21. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
[TBL] [Abstract][Full Text] [Related]
22. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Joshi SS; Maron SB; Catenacci DV
Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
[TBL] [Abstract][Full Text] [Related]
23. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
[TBL] [Abstract][Full Text] [Related]
24. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
[TBL] [Abstract][Full Text] [Related]
25. CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.
Schmalenberg H; Al-Batran SE; Pauligk C; Zander T; Reichart A; Lindig U; Kleiß M; Müller L; Bolling C; Seufferlein T; Reichardt P; Kullmann F; Eschenburg H; Schmittel A; Egger M; Block A; Goetze TO
J Cancer Res Clin Oncol; 2018 Mar; 144(3):559-569. PubMed ID: 29285668
[TBL] [Abstract][Full Text] [Related]
26. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
[TBL] [Abstract][Full Text] [Related]
27. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):16-8. PubMed ID: 12109800
[TBL] [Abstract][Full Text] [Related]
28. Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer.
Chau I; Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Sanchez T; Maglinte GA; Laurie M; Abraham P; Patel D; Shangguan T
Gastric Cancer; 2020 Jan; 23(1):133-141. PubMed ID: 31549264
[TBL] [Abstract][Full Text] [Related]
29. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
[TBL] [Abstract][Full Text] [Related]
30. Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.
Turkmen E; Erdogan B; Kodaz H; Hacibekiroglu I; Onal Y; Uzunoglu S; Kilic N; Cicin I
Acta Gastroenterol Belg; 2016; 79(2):211-5. PubMed ID: 27382940
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
32. What is the value of third-line chemotherapy in advanced gastroesophageal cancer? A 5-year retrospective analysis at a single center.
Lam JYC; Choo SP; Tai DW; Tan IBH; Tham CK; Koo WH; Ong SYK; Ang SF; Chua CWL; Chong DQ; Teo PTH; Lee CJZ; Ee SCE; Ng MCH
Asia Pac J Clin Oncol; 2020 Feb; 16(1):23-27. PubMed ID: 31736219
[TBL] [Abstract][Full Text] [Related]
33. Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients.
Davidson M; Cafferkey C; Goode EF; Kouvelakis K; Hughes D; Reguera P; Kalaitzaki E; Peckitt C; Rao S; Watkins D; Chau I; Cunningham D; Starling N
Clin Colorectal Cancer; 2018 Sep; 17(3):223-230. PubMed ID: 29980492
[TBL] [Abstract][Full Text] [Related]
34. Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis.
Zhou YJ; Lu XF; Meng JL; Wang XY; Zhang QW; Chen JN; Wang QW; Yan FR; Li XB
BMC Cancer; 2021 Jul; 21(1):771. PubMed ID: 34217249
[TBL] [Abstract][Full Text] [Related]
35. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis.
Ter Veer E; van den Ende T; Creemers A; de Waal L; van Oijen MGH; van Laarhoven HWM
Acta Oncol; 2018 Dec; 57(12):1599-1604. PubMed ID: 30264641
[TBL] [Abstract][Full Text] [Related]
36. Beyond Front-Line Therapy for Unresectable Gastroesophageal Adenocarcinoma: Are There Differences in Subsequent Therapy Sequencing?
Rogers JE; Wang X; Trail A; Ajani JA
Oncology; 2022; 100(3):182-187. PubMed ID: 34969028
[TBL] [Abstract][Full Text] [Related]
37. Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma.
Jiang DM; Suzuki C; Espin-Garcia O; Lim CH; Ma LX; Sun P; Sim HW; Natori A; Chan BA; Moignard S; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Jang RW; Elimova E
Cancer Med; 2020 May; 9(9):3023-3032. PubMed ID: 32130793
[TBL] [Abstract][Full Text] [Related]
38. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
[TBL] [Abstract][Full Text] [Related]
39. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
40. A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas.
Shankaran V; Xiao H; Bertwistle D; Zhang Y; You M; Abraham P; Chau I
Adv Ther; 2021 Jan; 38(1):707-720. PubMed ID: 33244736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]